<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04321460</url>
  </required_header>
  <id_info>
    <org_study_id>CT_002_LRG_CAP</org_study_id>
    <nct_id>NCT04321460</nct_id>
  </id_info>
  <brief_title>Study of LRG-002 Hard Capsules (Lek d.d., Slovenia) Used in the Prophylaxis of Antibiotic-associated Diarrhea in Adults.</brief_title>
  <official_title>Multicentre, Double-blind, Randomized, Placebo-controlled, Parallel-group Efficacy and Safety Study of LRG-002 Hard Capsules (Lek d.d., Slovenia) Used in the Prophylaxis of Antibiotic-associated Diarrhea in Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sandoz</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to investigate the efficacy and safety of LRG-002 investigational&#xD;
      medicinal product, capsules (Lek d.d., Slovenia) in comparison with placebo, as an adjunct&#xD;
      treatment for prophylaxis of antibiotic-associated diarrhea (AAD) in patients with acute&#xD;
      respiratory diseases (ARDs) receiving a standard antimicrobial therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, multi-center, double-blind, randomized, parallel-group clinical study.&#xD;
&#xD;
      The study will comprise the following periods:&#xD;
&#xD;
      I. Screening + randomization + treatment initiation: Visit 1 (Day 1) II. Blinded treatment&#xD;
      with LRG-002 or matching placebo in antibiotic-treated patients for a total of 14 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Actual">January 4, 2021</completion_date>
  <primary_completion_date type="Actual">January 4, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of occurrence of AAD</measure>
    <time_frame>14 days</time_frame>
    <description>AAD (antibiotic-associated diarrhea) is defined as diarrhea associated with the antibiotic use caused by C. difficile or of otherwise not identified etiology, upon analysis of stool samples and differential diagnostics according to investigator's judgment. Diarrhea is defined as loose or watery stool (Type 5-7 according to Bristol Stool Form Scale) three times a day (frequent bowel movements with formed stool is not considered as diarrhea) in accordance with WHO criteria; based on the diary data (BSFS) and confirmation of AAD by the investigator.. Diarrhea is assessed in a diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean number of bowel movements per day</measure>
    <time_frame>14 days</time_frame>
    <description>Bowel movements will be assessed based on the data of patient's diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of any diarrhea</measure>
    <time_frame>14 days</time_frame>
    <description>Incidence of any diarrhea will be assessed based on the data of patient's diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration of AAD</measure>
    <time_frame>14 days</time_frame>
    <description>The duration of AAD (the time from the onset of AAD to the normalization of stool form according to BSFS (types 1, 2, 3 and 4) and the presence of normal stool within 48 hours)) will be assessed based on the data of patient's diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration of any diarrhea</measure>
    <time_frame>14 days</time_frame>
    <description>The duration of any diarrhea (the time from the onset of diarrhea to the normalization of stool form according to BSFS (types 1, 2, 3 and 4) and the presence of normal stool within 48 hours)) will be assessed based on the data of patient's diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in stool consistency</measure>
    <time_frame>14 days</time_frame>
    <description>The changes in stool consistency (according to Bristol Stool Form Scale) will be assessed based on the data of patient's diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of gastrointestinal symptoms by severity</measure>
    <time_frame>14 days</time_frame>
    <description>The occurrence and severity of gastrointestinal symptoms, including nausea, vomiting, flatulence, abdominal pain and decreased appetite will be assessed based on the data of patient's diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of C. difficile-associated AAD</measure>
    <time_frame>14 Days</time_frame>
    <description>Incidence of C. difficile-associated AAD will be assessed based on the data of stool analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-C. difficile-associated AAD</measure>
    <time_frame>14 Days</time_frame>
    <description>Incidence of non-C. difficile-associated AAD will be assessed based on the data of stool analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body weight</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>Change from baseline in body weight will be assessed based on thet clinical data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization rate</measure>
    <time_frame>14 days</time_frame>
    <description>Hospitalization rate will be assessed based on the clinical data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of using standard symptomatic therapy</measure>
    <time_frame>14 days</time_frame>
    <description>The number of days of using standard symptomatic therapy (as &quot;rescue medication&quot;) to relieve symptoms of acute diarrhea will be assessed based on the clinical data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients using standard symptomatic therapy</measure>
    <time_frame>14 days</time_frame>
    <description>The number of patients using standard symptomatic therapy (as &quot;rescue medication&quot;) to relieve symptoms of acute diarrhea will be assessed based on the clinical data</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">520</enrollment>
  <condition>Antibiotic-associated Diarrhea</condition>
  <arm_group>
    <arm_group_label>LRG-002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LRG-002 once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LRG-002</intervention_name>
    <description>Capsules containing live lyophilized probiotic bacteria of Lactobacillus genus</description>
    <arm_group_label>LRG-002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules containing placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients will be considered eligible for study participation if they meet the following&#xD;
        inclusion criteria:&#xD;
&#xD;
          1. An Informed Consent Form for study participation voluntarily signed by a patient;&#xD;
&#xD;
          2. Male and female subjects, 18 to 65 years of age inclusive;&#xD;
&#xD;
          3. Antibacterial treatment for active ARDs started/to be started on the first day of the&#xD;
             study (7-day course of oral beta-lactam antibiotic). Only one AB should be used per&#xD;
             subject, in an outpatient setting. Diagnostic procedures of ARD and the prescription&#xD;
             of antibiotic therapy should be completed before signing of the Informed Consent Form.&#xD;
&#xD;
          4. Female patients will be considered as eligible for study participation if they are:&#xD;
             Unable to become pregnant or Capable of childbirth, but with negative pregnancy test&#xD;
             at the screening visit, and the patient agrees to continuously and properly use one a&#xD;
             following suitable methods of contraception Male participants,. together with their&#xD;
             partner, are to use appropriate contraception during the entire study period starting&#xD;
             from signing of the Informed Consent Form and until the study end, and for 30 days&#xD;
             after study completion;&#xD;
&#xD;
        6. The ability to understand the information about the clinical study, readiness to comply&#xD;
        with the study protocol requirements, ability to take the investigational products and&#xD;
        evaluate symptoms on his (or her) own using diary/questionnaires as per protocol; 7.&#xD;
        Ability to maintain the habitual lifestyle throughout the study, including diet. 8. Willing&#xD;
        not to consume any products containing probiotics during participation in the clinical&#xD;
        trial. 9. Willing not to take part in any other study during the present trial.&#xD;
&#xD;
        Patients will not be eligible for study enrollment if they have one or more of the&#xD;
        following criteria:&#xD;
&#xD;
          1. Any therapy (including medications, medical devices and dietary supplements) that can&#xD;
             influence the stool consistency, according to the Investigator's opinion, should not&#xD;
             be used within 14 days prior to Visit 1;&#xD;
&#xD;
          2. Use of immunosuppressive, immunostimulating and immunomodulating agents including&#xD;
             drugs of herbal origin and dietary supplements within 30 days prior to the study&#xD;
             start;&#xD;
&#xD;
          3. Use of anti-rejection medication after stem cell or solid organ transplant;&#xD;
&#xD;
          4. Use of systemic glucocorticosteroids within 8 weeks prior to the study start;&#xD;
&#xD;
          5. Use of proton pump inhibitors within 3 months prior to Visit 1;&#xD;
&#xD;
          6. Chemotherapy or radiation;&#xD;
&#xD;
          7. History of recurrent diarrhea;&#xD;
&#xD;
          8. Patient has diarrhea or loose stool within 2 days prior to the study start;&#xD;
&#xD;
          9. Patient has severe ARD expected to require an administration of antibiotics therapy&#xD;
             for more than 7 days or prescription of additional antibiotics;&#xD;
&#xD;
         10. Use of antimicrobials within 3 months prior to the study start;&#xD;
&#xD;
         11. Use of yeast/probiotic/fermented products within 2 weeks prior to the first visit;&#xD;
&#xD;
         12. Known allergy/hypersensitivity to the investigational medicinal product in the medical&#xD;
             history;&#xD;
&#xD;
         13. Immunocompromised patients;&#xD;
&#xD;
         14. Known digestion/absorption disorders of the gastrointestinal tract (e.g. inflammatory&#xD;
             bowel disease, celiacia, pancreatitis, motility disorders etc.) and/or&#xD;
             gastrointestinal surgery;&#xD;
&#xD;
         15. Known irritable bowel syndrome;&#xD;
&#xD;
         16. Known small intestinal bacterial overgrowth;&#xD;
&#xD;
         17. Patient has pyrexia of more than 38°C;&#xD;
&#xD;
         18. Pregnant and/or breastfeeding women;&#xD;
&#xD;
         19. Participation in other clinical trials of medicinal products or medical devices at the&#xD;
             screening Visit or within 30 days before the screening Visit;&#xD;
&#xD;
         20. Surgical intervention within 30 days before the screening visit or planned surgical&#xD;
             treatment during the trial (before a follow-up visit is completed), including&#xD;
             diagnostic procedures or inpatient stay;&#xD;
&#xD;
         21. Known or suspected alcohol and/or drug addiction;&#xD;
&#xD;
         22. A suspected low compliance or incapability of the patient to perform the procedures&#xD;
             and comply with restrictions according to the trial protocol (e.g., due to mental&#xD;
             disorders);&#xD;
&#xD;
         23. Potential for translocation of probiotic across bowel wall (Presence of an active&#xD;
             bowel leak, acute abdomen, active intestinal disease including colitis, or significant&#xD;
             bowel dysfunction; presence of neutropenia or anticipation of neutropenia after&#xD;
             chemotherapy; radiation therapy);&#xD;
&#xD;
         24. Any disorders of cardiovascular, renal, hepatic, gastrointestinal, endocrine and&#xD;
             nervous systems, or other conditions/diseases which, in the Investigator's opinion,&#xD;
             may render study participation unsafe for a patient or may affect a test result.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 24, 2020</study_first_submitted>
  <study_first_submitted_qc>March 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2020</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diarrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

